-
Product Insights
Polycystic Ovarian Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Ovarian Syndrome - Drugs In Development, 2023’, provides an overview of the Polycystic Ovarian Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Ovarian Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Ovarian Disease - Drugs In Development, 2023’, provides an overview of the Ovarian Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ovarian Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. The Polycystic ovarian syndrome pipeline market research report provides a comprehensive overview on the therapeutics under development for Polycystic ovary syndrome, complete with analysis by stage of...
-
Product Insights
Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome. The NASH drugs in development market research report provides comprehensive information on the...